Clinical Trial Update: A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols [NA]

View source ↗

Summary

Trial update describing a rollover protocol to allow continued access to tivozanib for subjects enrolled in other tivozanib protocols; study terminated with pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Tivozanib (tivozanib)

Snippet

Sponsor: AVEO Pharmaceuticals, Inc. | Conditions: Solid Tumors | NA | Status: TERMINATED | Results posted: 2020-09-01